Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) CEO James Lanthier and chief scientific officer Joseph Araujo joined Proactive's Stephen Gunnion after the US Patent and Trademark Office granted allowance for the company’s patent application covering its short-duration novel psychedelic medications for the treatment of central nervous system (CNS) disorders.
Lanthier telling Proactive that it comes on the heels of a notice of allowance the company received a few weeks ago on its Family 1 drug candidates, underscoring the strength of Mindset's IP (intellectual property) position.
Araujo said the company anticipates having IND (investigation new drug) in place for the CNS drug candidate in mid to third-quarter 2023.